Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity

Molecular Cancer Therapeutics

Volumn 4, Issue 10, 2005, Pages 1521-1532

  Stimson, Lindsay ^a   Rowlands, Martin G ^a   Newbatt, Yvette M ^a   Smith, Nicola F ^a   Raynaud, Florence I ^a   Rogers, Paul ^a   Bavetsias, Vassilios ^a   Gorsuch, Stephen ^a   Jarman, Michael ^a   Bannister, Andrew ^b   Kouzarides, Tony ^b   McDonald, Edward ^a   Workman, Paul ^a   Aherne, G Wynne ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; ANTINEOPLASTIC AGENT; CCT 004463; CCT 004464; CCT 004465; CCT 004466; CCT 004467; CCT 077791; CCT 077792; CCT 077796; CCT 079769; CCT 129182; CCT 129183; CCT 129184; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; ISOTHIAZOLONE DERIVATIVE; PROTEIN P300; THIOL GROUP; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CELL METABOLISM; COLON TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INCUBATION TIME; PRIORITY JOURNAL; PROTEIN BINDING; TUMOR CELL LINE; TUMOR GROWTH;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HCT116 CELLS; HISTONE ACETYLTRANSFERASES; HISTONES; HT29 CELLS; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TRANSCRIPTION FACTORS;

EID: 27644473204     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0135     Document Type: Article

References (51)

1. Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:41-5.
2. Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-9.
3. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202.
4. Bernstein BE, Schreiber SL. Global approaches to chromatin. Chem Biol 2002;9:1167-73.
5. Cress WD, Seto E. Histone deacetylases transcriptional control and cancer. J Cell Physiol 2000;184:1-16.
6. Liu Y, Colosimo AL, Yang X-J, Liao D. Adenovirus E1B 55-kilodalton oncoprotein inhibits p53 acetylation by PCAF. Mol Cell Biol 2000;20: 5540-53.
7. Hubbert C, Guardiola A, Shao R, et al. HDAC6 is a microtubule-associated deacetylase. Nature 2002;417:455-8.
8. de Ruijter AJM, Gennip AHV, Caron HN, Kemp S, van Kuilenberg ABP. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003;370:737-49.
9. Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem 2001;70:8-120.
10. Kristeleit R, Stimson L, Workman P, Aherne W. Histone modifications enzymes: novel targets for cancer drugs. Expert Opin Emerg Drugs 2004; 9:135-54.
11. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999;9:40-8.
12. Mahlknecht U, Hoelzer D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 2000;6:623-44.
13. Gray S, The B. Histone acetylation/deacetylation and cancer: an "open" and "shut" case? Curr Mol Med 2001; 1:401-29.
14. Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci 2001;58:728-36.
15. Reiter R, Wellstein A, Riegel AT. An isoform of the coactivator AIB1 that increases hormone and growth factor sensitivity is overexpressed in breast cancer. J Biol Chem 2001;276:39736-41.
16. Anzick SL, Kononen J, Walker RL, et al. AIB1 a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277: 965-9.
17. Sakakura C, Hagiwara A, Yasuoka R, et al. Amplification and overexpression of the AIB1 nuclear receptor co-activator gene in primary gastric cancers. Int J Cancer 2000;89:217-23.
18. Aguiar RCT, Chase A, Coulthard S, et al. Abnormalities of chromosome band 8p11 in leukaemia: two clinical syndromes can be distinguished on the basis of MOZ involvement. Blood 1997;90:3130-5.
19. Panagopoulos I, Fioretos T, Isaksson M, et al. Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). Hum Mol Gen 2001;10:395-404.
20. Sakai K, Nagahara H, Abe K, Obata H. Loss of heterozygosity on chromosome 16 in hepatocellular carcinoma. J Gastroenterol Hepatol 1992;7:288-92.
21. Muraoka M, Konishi M, Kikuchi-Yanoshita R, et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996;12:1565-9.
22. Gayther SA, Batley SJ, Linger L, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000;24:300-3.
23. Ionov Y, Matsui S, Cowell JK. A role for p300/CREB binding protein genes in promoting cancer progression in colon cancer cell lines with microsatellite instability. Proc Natl Acad Sci U S A 2004;101:1273-8.
24. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DAL, Tindall DJ. p300 in prostate cancer proliferation and progression. Cancer Res 2003; 63:7638-40.
25. Lau OD, Kundu TK, Soccio RE, et al. HATS off: selective synthetic inhibitors of the histone acetyltransferase p300 and PCAF. Mol Cell 2000;5:589-95.
26. Balasubramanyam K, Swaminathan V, Ranganathan A, Kundu TK. Small molecule modulators of histone acetyltransferase p300. J Biol Chem 2003;278:19134-40.
27. Balasubramanyam K, Varier RA, Altaf M, et al. Polyisoprenylated benzophenone, garcinol, a natural HAT inhibitor represses chromatin transcription and alters global gene expression. J Biol Chem 2004;77: 33716-26.
28. Balasubramanyam K, Altaf M, Varier RA, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase-dependent chromatin transcription. J Biol Chem 2004;279:51163-71.
29. Turlais F, Hardcastle A, Rowlands M, et al. High-throughput screening for identification of small molecule inhibitors of histone acetyltransferases using scintillating microplates (FlashPlate). Anal Biochem 2001;298:62-8.
30. Bannister AJ, Kouzarides T. The CBP coactivator is a histone acetyltransferase. Nature 1996;384:641-3.
31. Aherne GW, Rowlands MG, Stimson L, Workman P. Assays for the identification and evaluation of histone acetyltransferase inhibitors. Methods 2002;26:245-53.
32. Martinez-Balbas MA, Bannister AJ, Martin K, Haus-Seuffert P, Meisterernst M, Kouzarides T. The acetyltransferase activity of CBP stimulates transcription. EMBO J 1998;17:2886-93.
33. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anti-cancer-drug screening. J Natl Cancer Inst 1990; 82:1107-18.
34. Trevillyan JM, Chiou XG, Ballaron SJ, et al. Inhibition of p56Ick tyrosine kinases by isothiazolones. Arch Biochem Biophys 1999;364:19-29.
35. Yu X, Guo S, Marcu MG, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells lines by depsipeptide FR901228. J Nat Inst Cancer 2002;94:504-12.
36. Jeong J, Bae M, Ahn M, et al. Regulation and destabilisation of HIF-1α by ARD1-mediated acetylation. Cell 2002;111:709-20.
37. Zhang Y, Li N, Caron C, et al. HDAC-6 interacts with and deacetylases tubulin and microtubules in vivo. EMBO J 2003;22:1168-79.
38. Minucci S, Nervi C, Coco FL, Pelicci PG. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene 2001;20:3110-5.
39. Ida K, Kitabayashi I, Taki T, et al. Adenoviral E1A-associated protein p300 is involved in acute myeloid leukaemia with t(11;22)(q23;q13). Blood 1997;90:4699-704.
40. Bandyopadhyay D, Okan NA, Bales E, Nascimento L, Cole PA, Medrano EE. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res 2002;62:6231-9.
41. Iyer NG, Chin S-F, Ozdag H, et al. p300 regulates p53-dependent apoptosis after DNA damage in colorectal cancer cells by modulation of PUMA/p21 levels. Proc Natl Acad Sci U S A 2004;101:7386-91.
42. Blagosklony MV, Robey R, Sackett DL, et al. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest and cytotoxicity. Mol Cancer Ther 2002;1:937-41.
43. Stimson L, Rowlands MG, Newbatt Y, et al. Isothiazolones as novel inhibitors of PCAF and p300 histone acetyltransferase activity. Clin Cancer Res 2003;9:87.
44. Collier P, Ramsey A, Waigh R, Douglas K, Austin P, Gilbert P. Chemical reactivity of some isothiazolone biocides. J Appl Bacteriol 1990; 69:578-84.
45. Devos R, Guisez Y, Plaetinck G, et al. Covalent modification of the interleukin-5 receptor by isothiazolones leads to inhibition of the binding of interleukin-5. J Biochem 1994;225:635-40.
46. Hayakawa N, Nozawa K, Ogawa A, et al. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Biochemistry 1999;38:11501-7.
47. Tanner KG, Langer MR, Kim Y, Denu JM. Kinetic mechanism of the histone acetyltransferase GCN5 from yeast. J Biol Chem 2000;275: 22048-55.
48. Biel M, Kretsovali A, Karatzali E, Papamatheakis J, Giannis A. Design, synthesis and biological evaluation of a small molecule inhibitor of the histone acetyltransferase GCN5. Angew Chem Int Ed 2004;43: 3974-6.
49. Ogryzko VV. Mammalian histone acetyltransferases and their complexes. Cell Mol Life Sci 2001;58:683-92.
50. Sagar V, Zheng W, Thompson PR, Cole PA. Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors. Bioorg Med Chem 2004;12:3383-90.
51. Zheng Y, Thompson PR, Cebrat M, et al. Selective HAT inhibitors as mechanistic tools for protein acetylation: Methods Enzymol 2004;376: 188-99.